MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
17.50
+3.30 (23.24%)
At close: Aug 13, 2025, 4:00 PM
14.75
-2.75 (-15.71%)
Pre-market: Aug 14, 2025, 8:59 AM EDT
MiNK Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for MiNK Therapeutics stock ranges from a low of $35 to a high of $40. The average analyst price target of $37.5 forecasts a 114.29% increase in the stock price over the next year.
Price Target: $37.50 (+114.29%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 15, 2025.
Analyst Ratings
The average analyst rating for MiNK Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $35 | Strong Buy → Hold | Downgrades | $35 | +100.00% | Jul 15, 2025 |
William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +100.00% | Mar 18, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $35 | Strong Buy | Maintains | $9 → $35 | +100.00% | Feb 25, 2025 |
Baird | Baird | Buy Maintains $80 → $40 | Buy | Maintains | $80 → $40 | +128.57% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.01
from -2.86
EPS Next Year
-1.88
from -2.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.61 | -0.91 | -0.78 | ||
Avg | -2.01 | -1.88 | -1.76 | ||
Low | -2.37 | -2.76 | -2.67 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.